Psoriatic Arthritis: Pharmacotherapy Update

Psoriatic Arthritis: Pharmacotherapy Update,10.1007/s11926-010-0108-z,Current Rheumatology Reports,Philip J. Mease

Psoriatic Arthritis: Pharmacotherapy Update   (Citations: 1)
BibTex | RIS | RefWorks Download
Psoriatic arthritis is a systemic disorder that causes chronic pain, altered physical appearance, and loss of function. The clinical features are diverse, but the core manifestations are psoriasis, peripheral arthritis, axial disease, enthesitis, and dactylitis. Our understanding about the psoriatic arthritis disease state, assessment, and treatment has advanced thanks to significant collaborative efforts by rheumatologists and dermatologists in the development of classification criteria, outcome measures to assess the various clinical domains, and treatment trials with agents also used for diseases such as rheumatoid arthritis and psoriasis. In particular, biologic agents, especially anti-tumor necrosis factor agents, have demonstrated significant efficacy and reasonable safety in all clinical domains of the disease, resulting in amelioration of clinical symptoms, inhibition of structural damage, and improvement in function and quality of life.
Journal: Current Rheumatology Reports , vol. 12, no. 4, pp. 272-280, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: